HT9425-23-PCARP-IDA: DOD Pancreatic Cancer, Idea Development Award
Closed
This grant is closed. A newer notice from the same program is open now: DoW Breast Cancer, Clinical Research Extension Award (HT942526BCRPCREA2). Status: Closes November 18, 2026 (11 days left). It is in our archive of Defense Health Agency Contracting Activity - DHACA notices from 2023.
Defense Health Agency Contracting Activity - DHACA offered grants to any type of organization. It expected to make about 8 awards worth $7.4 million in total. Applications closed on October 5, 2023.
From the official notice on Grants.gov, last changed April 17, 2023. Checked November 7, 2026.
- Total funding$7.4 million
- Expected awards8
- Cost sharingNot required
- Funding typeCooperative Agreement, Grant
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| HT942524PCARPIDA | April 29, 2024 | Closed October 3, 2024 | Closed |
| W81XWH-22-PCARP-IDA | April 25, 2022 | Closed October 6, 2022 | Closed |
| W81XWH-21-PCARP-IDA | May 18, 2021 | Closed October 1, 2021 | Closed |
Key dates
| Posted | April 17, 2023 |
|---|---|
| Deadline | October 5, 2023 |
| Archived by Grants.gov | November 4, 2023 |
Who can apply
This opportunity was open to any type of organization.
- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
Is this a realistic fit?
- Most of the program's money (59% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The PCARP Idea Development Award supports the development of innovative, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for individuals with pancreatic cancer. This award mechanism is designed to support innovative ideas with the potential to yield impactful data and new avenues of investigation. Significant features of the Idea Development Award: • Impact: The proposed research is expected to make an important and original contribution to advancing the understanding of pancreatic cancer and ultimately lead to improved outcomes for individuals with pancreatic cancer. The project’s impact on both pancreatic cancer research and patient care should be articulated, even if clinical impact is not an immediate outcome. • Innovation: Research deemed innovative may represent a new paradigm, challenge existing paradigms, look at existing problems from new perspectives, or exhibit other highly creative qualities. Research may be innovative in study concept, research methods or technology, or adaptations of existing methods or technologies. Research that represents an incremental advance on previously published work is not considered innovative. • Personnel: Personnel are considered a crucial element of the FY23 PCARP Idea Development Award. At least one member of the research team should have experience in pancreatic cancer research, as demonstrated by recent publications and funding. Inclusion of a biostatistician in the study team is encouraged. • Research must be based on preliminary data: Although the proposed research must have direct relevance to pancreatic cancer, the required preliminary data, which may include unpublished results from the laboratory of the Principal Investigator(s) (PI[s]), research team, or collaborators named on the application, may be from outside the pancreatic cancer research field. Research should also be based on a sound scientific rationale that is established through logical reasoning and critical review and analysis of the literature. Partnering PI Option for Early-Career Investigator: The FY23 Idea Development Award mechanism is offering a higher level of funding for applications that propose to partner an experienced PI (i.e., Initiating PI, who will serve as the mentor) with an Early-Career Investigator (i.e., Partnering PI) wishing to pursue a career in pancreatic cancer research.
Who has won Military Medical Research and Development grants before
From fiscal 2021 to 2025, Military Medical Research and Development (12.420) awarded $6.9 billion across 5,470 grant awards, an average of $1.3 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. | Maryland | 81 | $546 million |
| The Univeristy of Texas M.D. Anderson Cancer Center | Texas | 139 | $166 million |
| The Johns Hopkins University | Maryland | 157 | $153 million |
| The Regents of the University of California, San Francisco | California | 113 | $147 million |
| Duke University | North Carolina | 86 | $123 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, HT942526BCRPCREA2, which is open now.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is HT9425-23-PCARP-IDA still open?
No. It closed on October 5, 2023. A newer notice is open: HT942526BCRPCREA2, closes November 18, 2026 (11 days left).
Who can apply for DOD Pancreatic Cancer, Idea Development Award?
Defense Health Agency Contracting Activity - DHACA accepted applications from any type of organization.
What is the deadline for DOD Pancreatic Cancer, Idea Development Award?
Closed October 5, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
About $7.4 million in total across about 8 awards.
Who has won Military Medical Research and Development grants before?
The largest recipients over five fiscal years were The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Univeristy of Texas M.D. Anderson Cancer Center, The Johns Hopkins University. The program made 5,470 awards worth $6.9 billion in that time.